VUSION Drug Patent Profile

When do Vusion patents expire, and when can generic versions of Vusion launch?

Vusion is a drug marketed by Mylan and is included in one NDA. There is one patent protecting this drug.

This drug has one patent family member in one country.

The generic ingredient in VUSION is miconazole nitrate; white petrolatum; zinc oxide. There are twenty-eight drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the miconazole nitrate; white petrolatum; zinc oxide profile page.

DrugPatentWatch^® Generic Entry Outlook for Vusion

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 30, 2028. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for VUSION

International Patents:	1
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	114
Clinical Trials:	2
Patent Applications:	4,257
Drug Prices:	Drug price information for VUSION
What excipients (inactive ingredients) are in VUSION?	VUSION excipients list
DailyMed Link:	VUSION at DailyMed

See drug prices for VUSION

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for VUSION

Constraining patent/regulatory exclusivity:

4,911,932

NDA:

021026

Dosage:

OINTMENT;TOPICAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for VUSION

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Image Dermatology P.C.	Early Phase 1
Stiefel, a GSK Company	Phase 4
GlaxoSmithKline	Phase 4

See all VUSION clinical trials

Pharmacology for VUSION

Drug Class

Azole Antifungal

US Patents and Regulatory Information for VUSION

VUSION is protected by one US patents.

This potential generic entry date is based on patent 4,911,932.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mylan	VUSION	miconazole nitrate; white petrolatum; zinc oxide	OINTMENT;TOPICAL	021026-001	Feb 16, 2006		RX	Yes	Yes	8,147,852

Expired US Patents for VUSION

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Mylan	VUSION	miconazole nitrate; white petrolatum; zinc oxide	OINTMENT;TOPICAL	021026-001	Feb 16, 2006	4,911,932

International Patents for VUSION

See the table below for patents covering VUSION around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	1250522	COMPOSITIONS POUR SOINS DERMATOLOGIQUES (SKIN CARE COMPOSITIONS)
Hong Kong	8290	SKIN CARE COMPOSITIONS
Singapore	66489
Zimbabwe	1185	SKIN CARE COMPOSITIONS

Market Dynamics and Financial Trajectory for the Pharmaceutical Industry: Insights and Trends

Introduction

The pharmaceutical industry is undergoing significant transformations driven by various market dynamics, technological advancements, and changing regulatory landscapes. This article delves into the key factors influencing the market, particularly focusing on the generic drugs sector, and examines the financial trajectory of companies within this industry.

Current Market Size and Growth Projections

The generic drugs market is substantial and growing. As of 2024, the market is estimated to be worth $450.7 billion and is projected to grow at a Compound Annual Growth Rate (CAGR) of 5.3% until 2034[1].

Drivers of Market Growth

Rising Government Initiatives

Governments worldwide are increasingly promoting the use of generic drugs due to their economic and public health benefits. Initiatives such as generic substitution, incentives for healthcare providers to prescribe generics, and public awareness campaigns are driving the adoption of generic medications. These efforts streamline the approval process, ensure faster market entry, and increase competition, thereby fostering market growth[1].

Rise in Chronic Diseases

The escalating prevalence of chronic diseases like cardiovascular diseases, diabetes, and respiratory disorders is creating a high demand for cost-effective treatment options. Generic drugs, being therapeutically equivalent to brand-name drugs but more affordable, are becoming a critical solution for managing these conditions. This trend is expected to significantly drive the growth of the generic drugs market[1].

Patent Expiration of Blockbuster Drugs

The patent expiration of several blockbuster drugs presents a significant opportunity for generic drug manufacturers. As these patents expire, generic versions of previously exclusive medications can enter the market, offering patients cost-effective alternatives and contributing to healthcare system sustainability[1].

Growth of Biologics and Biosimilars

The expansion of the biologics market and the development of biosimilars offer another growth avenue for the generic drugs sector. Biosimilars provide cost-effective alternatives to biologic drugs, reducing the overall cost burden on healthcare systems and increasing patient access to advanced therapies[1].

Financial Trajectory of Pharmaceutical Companies

Revenue Growth and Order Intake

Companies like VusionGroup are experiencing robust growth, driven by strong momentum in regions such as North America. For instance, VusionGroup reported a 13% increase in adjusted sales in the first half of 2024, with a record level of orders at €714 million, up 38% from the previous year. This growth is expected to continue, with the company targeting adjusted sales above €1 billion for the full year[2].

Geographic Performance

The geographic performance of pharmaceutical companies is also noteworthy. VusionGroup's growth, for example, is heavily driven by North America, with significant commercial successes in Europe as well. This diversified geographic performance helps in mitigating regional market risks and ensures sustained growth[2].

Recurring and Non-Recurring Services

The revenue mix between recurring and non-recurring services is another important aspect. VusionGroup saw a 28% increase in recurring services revenue, which now accounts for nearly 60% of total Value-Added Services (VAS) revenue. However, non-recurring services declined due to economic constraints, but are expected to rebound in the second half of the year[2].

Market Opportunities and Challenges

Patent and Regulatory Landscape

The patent expiration of blockbuster drugs and the streamlining of regulatory approvals are key opportunities for generic drug manufacturers. However, these companies must also navigate the complexities of patent laws and regulatory requirements to ensure timely market entry[1].

Technological Advancements

Technological advancements, such as the development of biosimilars and radioconjugates, are transforming the pharmaceutical landscape. Companies like AstraZeneca are acquiring specialized firms to accelerate the development of next-generation therapies, highlighting the importance of innovation in driving market growth[4].

Economic and Supply Chain Challenges

The COVID-19 pandemic exposed vulnerabilities in the supply chains of pharmaceutical companies, leading to raw material shortages and production slowdowns. Companies must invest in robust supply chains and transparent regulations to ensure sustainable access to medications[1].

Key Takeaways

• The generic drugs market is projected to grow significantly, driven by government initiatives, the rise in chronic diseases, and the patent expiration of blockbuster drugs.
• Companies like VusionGroup are experiencing strong revenue growth and record order intake, particularly in regions like North America.
• The mix between recurring and non-recurring services is crucial for sustained revenue growth.
• Technological advancements and strategic acquisitions are key to driving innovation and market expansion.
• Addressing supply chain vulnerabilities and regulatory challenges is essential for maintaining market stability.

FAQs

Q: What is the projected growth rate of the generic drugs market? A: The generic drugs market is projected to grow at a CAGR of 5.3% from 2024 to 2034[1].

Q: How are government initiatives impacting the generic drugs market? A: Governments are promoting generic drugs through initiatives like generic substitution, incentives for healthcare providers, and public awareness campaigns, which are driving market growth[1].

Q: What role do biosimilars play in the pharmaceutical market? A: Biosimilars offer cost-effective alternatives to biologic drugs, reducing healthcare costs and increasing patient access to advanced therapies[1].

Q: How has the COVID-19 pandemic affected the pharmaceutical industry? A: The pandemic highlighted supply chain vulnerabilities, led to raw material shortages, and caused production slowdowns, but also accelerated the adoption of generic drugs due to increased healthcare needs[1].

Q: What are the key geographic regions driving growth for pharmaceutical companies like VusionGroup? A: North America is a significant driver of growth, with additional commercial successes in Europe contributing to overall revenue[2].

Sources

1. Generic Drugs market is projected to grow at a CAGR of 5.3% by 2034 - GlobeNewswire
2. VusionGroup - First Half 2024 Sales - Vusion
3. Insights into Ophthalmic Drug Innovations and Market Trends - Biochempeg
4. AstraZeneca to acquire Fusion to accelerate the development of ... - AstraZeneca
5. Qnovia, Inc. Raises $16 Million in Series B Financing to Advance ... - BioSpace